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ABSTRACT
Healthcare policies regarding hematopoietic stem cell transplantation (HSCT) must address the need for the
procedure as well as the availability of stem cell sources: bonemarrow, peripheral blood, or umbilical cord blood
(UCB). However, data with respect to the lifetime probability of undergoing HSCT are lacking. This study was
undertaken to estimate the latter probability in the United States (U.S.), depending on age, sex, and race. We
used data from the Center for International Blood and Marrow Transplant Research, the U.S. Surveillance,
Epidemiology and End Results Program, and the U.S. Census Bureau and calculated probabilities as cumulative
incidences. Several scenarios were considered: assuming current indications for autologous and allogeneic
HSCT, assuming universal donor availability, and assuming broadening of HSCT use in hematologic malignan-
cies. Incidences of diseases treated with HSCT and of HSCTs performed increase with age, rising strongly after
age40.Among individuals older than40, incidences arehigher formen than forwomen.The lifetimeprobabilities
of undergoing HSCT range from 0.23% to 0.98% under the various scenarios. We conclude that, given current
indications, the lifetimeprobability of undergoing autologous or allogeneicHSCT ismuchhigher thanpreviously
reported by others and could rise even higher with increases in donor availability and HSCT applicability.
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Hematopoietic stem cell transplantation (HSCT)
is an effective therapy for many life-threatening malig-
nant and nonmalignant diseases. Depending on the
situation, a patient’s own (autologous) cells or (alloge-
neic) cells from a donor are used. Presently, cells for
HSCT can be collected from bone marrow, peripheral
blood, or umbilical cord blood (UCB) (reviewed in
[1-4]).
In planning U.S. healthcare policies, especially
with regard to allocating resources for donor registries
and UCB banking, estimates of the probability that
one will need an HSCT during one’s life are critical,
but data regarding this probability are lacking.
The objective of this study was to calculate the
lifetime probability of undergoing HSCT in the
United States (U.S.) under various scenarios and its316dependence on age, sex, and race. The calculations in
this study are pertinent to all sources of hematopoietic
stem cells for transplantation.
MATERIALS AND METHODS
Data Sources
HSCT data were obtained from the Center for
International Blood and Marrow Transplant Research
(CIBMTR) for patients up to age 70 years (generally
the maximum transplant age), who received an
HSCT for any indication in the U.S. in 2001-2003.
The organization of the CIBMTR and its methods
for data collection and management are described
elsewhere [5].
Because reporting transplants to CIBMTR is
voluntary, the database does not include all HSCTs
performed. Currently there is no U.S. database that
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on data available from the National Marrow Donor
Program (NMDP), which collects data on most
(.90%) unrelated donor transplants in the U.S., the
Bone Marrow Transplant Information Network (BMT
Infonet), which attempts to survey all U.S. transplant
centers yearly, and the U.S. Hospital Discharge Data-
base from the Health Cost Utilization Project (HCUP),
we estimate that in the previously mentioned years the
CIBMTR collected transplant data on about 55% of
autologous and 50% of allogeneic HSCTs performed
in the U.S. Therefore, CIBMTR autologous and allo-
geneic HSCT numbers were multiplied by 1.82 and 2,
respectively, to estimate total numbers of HSCTs in
the U.S. These adjustment factors were applied uni-
formly to all subgroups of patients reported to the
CIBMTR and described in Table 1, assuming that
the cases reported to the CIBMTR are a random
sample of all HSCTs performed in the U.S. Thisassumption appears to be justified by comparison
with data collected by the organizations listed above.
The distribution of diseases and transplant types is
also similar to the distribution in the Europe-wide
survey of transplant activity conducted yearly by the
European Group for Blood and Marrow Transplanta-
tion (EBMT) [6].
The incidences of malignancies commonly treated
with HSCT were obtained from the Surveillance,
Epidemiology, and End Results (SEER) Program of
the U.S. National Cancer Institute (NCI) [7]. SEER
data are derived from registries covering approxi-
mately 26% of the U.S. population and do not include
nonmalignant HSCT indications [7]. We used the
SEER 13 database, which contains cases diagnosed
from 1992 to 2002 [7]. Using publicly available
software (SEER*Stat, version 6.1.4), we calculated
incidence rates per 100,000 persons up to age 70 years
for the years 2000-2002. Considering children andTable 1. Average Annual HSCT Numbers, under 4 Scenarios* †
Scenario 1 (%) Scenario 2 (%) Scenario 3 (%) Scenario 4 (%)
Total number of HCTs 7,811 (100) 9,480 (100) 16,796 (100) 32,484 (100)
Male recipients 4,434 (57) 5,644 (60) 9,826 (59) 18,619 (57)
Race
Caucasian 6,310 (81) 7,192 (76) 13,104 (78) 27,215 (84)
African-American 831 (11) 750 (8) 1,532 (9) 3,765 (12)
Other 670 (9) 1,538 (16) 2,160 (13) 1,504 (5)
Cases for ages\20 years 641 (100) 1,716 (100) 2,335 (100) 4,972 (100)
Leukemia 22 (3) 1,060 (62) 1,060 (45) 1,748 (35)
Non-Hodgkin lymphoma 47 (7) 64 (4) 111 (5) 464 (9)
Hodgkin disease 92 (14) 10 (1) 102 (4) 447 (9)
Multiple myeloma 0 (0) 0 (0) 0 (0)
Neuroblastoma 235 (37) 6 (0) 241 (10) 310 (6)
CNS tumors 125 (20) 0 (0) 125 (5) 1,173 (24)
Sarcoma 64 (10) 0 (0) 64 (3) 830 (17)
Myelodysplasia 1 (0) 42 (2) 42 (2)
Aplastic anemia 0 (0) 174 (10) 174 (7)
Other malignancies‡ 51 (8) 6 (0) 57 (2)
Other nonmalignant diseases§ 5 (1) 354 (21) 359 (15)
Cases for ages 20-70 years 7,170 (100) 7,764 (100) 14,461 (100) 27,512 (100)
Leukemia 459 (6) 4,294 (55) 4,294 (30) 7,390 (27)
Non-Hodgkin lymphoma 2,330 (32) 1,436 (18) 3,766 (26) 13,626 (50)
Hodgkin disease 858 (12) 106 (1) 964 (7) 2,850 (10)
Multiple myeloma 2,961 (41) 322 (4) 3,284 (23) 3,646 (13)
Neuroblastoma 3 (0) 0 (0) 3 (0)
CNS tumors 21 (0) 2 (0) 23 (0)
Sarcoma 33 (0) 8 (0) 41 (0)
Myelodysplasia 15 (0) 956 (12) 956 (7)
Aplastic anemia 0 (0) 204 (3) 204 (1)
Other malignancies‡ 427 (6) 370 (5) 797 (6)
Other nonmalignant diseases§ 63 (1) 66 (1) 129 (1)
CNS indicates central nervous system; HSCT, hematopoietic stem cell transplantation.
*For a description of the 4 scenarios, see the Materials and Methods section.
†The numbers under scenario 3 do not always equal the total of scenario 1 plus scenario 2. For an explanation, see the Materials and Methods
section.
‡Other malignancies: breast cancer, ovarian cancer, germ cell tumors, renal cell carcinoma, lung cancer, hepatobiliary cancer, pancreatic cancer,
cervical cancer, colorectal malignancies, small-cell lung cancer, prostate cancer, melanoma, other not specified or missing diagnosis.
§Other nonmalignant diseases: sickle cell anemia, thalassemia, Fanconi anemia, Diamond blackfan anemia, Glanzmann thromboasthenia,
congenital amegakaryocytic thrombocytopenia, other congenital platelet abnormalities not otherwise specified, autoimmune disorders, severe
combined immunodeficiency syndromes, other diagnosis (not reported). Data on nonmalignant diseases are not available through SEER.
318 J. J. Nietfeld et al.adults separately (see Table 1), only diagnoses that ac-
counted for 5% or more of the HSCTs in the
CIBMTR database were included; diseases for which
transplants are rarely done were not considered. Dis-
ease incidences were also calculated separately by age
decades as described in Table 2.
Scenarios
We calculated the probability of undergoing
HSCT, for people in the U.S., by age 70 years, under
four different scenarios (* 5 under current indica-
tions): (1) when the HSCT is autologous*; (2) when
the HSCT is allogeneic with universal donor availabil-
ity*. For this scenario it was assumed that there would
be no restriction in the availability of an HLA-identical
sibling (or comparable) donor. Because in reality only
30% of allograft candidates have an HLA-identical
sibling [8,9], the actual number of such transplants
was multiplied by 3, to estimate the ‘‘unrestricted’’
number of allogeneic HSCTs in a setting of universal
donor availability. Some patients without an
HLA-identical sibling currently receive allogeneic
transplants from alternative donors; we did not include
those numbers in this calculation. (3) When the HSCT
is either autologous* or allogeneic * with universal
donor availability. For this scenario, the HSCT
numbers under scenarios 1 and 2 are combined. In
arriving at these combined numbers, we assumed
that patients currently receiving autologous trans-
plants for diseases where allotransplants are generally
preferred would receive an allotransplant if a donor
were available, such as transplantation for leukemia.
Consequently, numbers of autotransplants for acute
and chronic leukemia included in scenario 1 were not
included in the numbers for scenario 3, because they
were already counted under scenario 2 (in the multipli-
cation by 3, assuming universal donor availability). (4)
Table 2. Incidence per 100,000 of Malignant Diseases Most Commonly
Treated with Hematopoietic Stem Cell Transplantation
Decades
Diseases 0-10 10-20 20-30 30-40 40-50 50-60 60-70
Leukemia 5.8 2.9 2.3 3.4 5.5 12.0 28.0
Non-Hodgkin
lymphoma
0.7 1.6 2.7 5.7 12 25.0 47.1
Hodgkin disease 0.2 1.9 4.1 3.5 2.7 2.2 3.1
Multiple myeloma — — 0.06 0.5 2.0 7.6 17.2
Neuroblastoma* 1.5 0.1 — — — — —
CNS tumors* 3.5 2.3 — — — — —
Sarcomas* 1.3 2.8 — — — — —
CNS indicates central nervous system.
Seer database from 2000 to 2002.
*CNS tumors and sarcomas are prevalent in patients older than 19
years; however, it is not a common indication for hematopoietic
stem cell transplantation in older patients and thus not included in
the table after this age; neuroblastoma is uncommon in patients older
than 19 years.When the HSCT is either autologous or allogeneic
AND there is universal donor availability AND
current indications are expanded so that 50% of the
patients with cancers treatable with HSCT receive
a transplant. In planning this scenario, we compared
the incidence of the cancers treatable with HSCT
with the estimated annual number of HSCTs
performed. This indicated that 15%-20% of adults
younger than 70 years with these cancers received
HSCT. This varied according to specific indication.
For example, the proportion of patients with leukemia
receiving HSCT was 10%-15%. The proportion of
children with neuroblastoma receiving HSCT was
about 35%, and the proportion of adults (younger
than 70) with multiple myeloma (MM)/S receiving
HSCT was 40%-45%. Considering these percentages,
we took 50% as an ‘‘upper limit’’ for scenario 4 and cal-
culated the numbers of HSCTs that would be per-
formed if half of the patients with 1 of all the diseases
treatable with HSCT would receive a transplant.
The ‘‘upper limit’’ was not set at 100%, because under
any envisioned circumstance a considerable number of
patients would receive therapies other than HSCT for
a variety of reasons including having low-risk disease
or highly refractory disease, comorbidities, or socio-
economic factors.
Statistical Analysis
First, the average annual incidences of HSCT per
100,000 people were computed by age decade under
each scenario. Incidences of SEER diagnoses per
100,000 people were normalized to average mid-year
U.S. population between the years 2001-2003 [10].
Next, the probability of receiving an HSCT was
calculated as a cumulative incidence under each sce-
nario, using the cumulative incidence estimator with
death in the absence of HSCT as a competing risk
[11,12]. To calculate the cumulative incidences, the
proportion of individuals at a particular age who are
mathematically ‘‘at risk’’ to undergo an HSCT (ie,
the proportion of individuals at that age who are alive
without an HSCT), was approximated by the overall
probability of being alive at that age, utilizing data
from the U.S. life tables for 2002 [13]. It is not possible
to obtain the actual proportion of individuals in the
overall population at risk at a given age; however, be-
cause the proportion of patients actually receiving
transplantation or being diagnosed with a transplant-
able disease is very small, the proportion at risk is quite
close to the proportion of individuals alive at a given
age. The yearly increment in the cumulative incidence
estimate is the proportion of individuals alive at the be-
ginning of the year times the incidence of receiving an
HSCT in the next year. Although the patient popula-
tions reported to the CIBMTR are adjusted for under-
reporting, individual patient-level data is not needed to
perform this calculation. Because these calculations
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able in standard software packages. An SAS/IML
program was written to perform the cumulative inci-
dence calculations.
Probabilities were also calculated for subgroups of
patients defined by sex and race. Race classifications
for HSCT recipients and for the population of patients
with hematologic malignancies were made by
CIBMTR and SEER, respectively. Because of differ-
ences in classification by CIBMTR and SEER data-
bases, racial subgroup analysis for incidences and
lifetime probabilities were limited to Caucasians and
African-Americans.
RESULTS
Numbers of Transplants under Scenarios (1-4)
Table 1 depicts the average annual total of U.S.
HSCTs under each scenario and the distribution of
HSCTs by sex, race, and transplant indication (plus
the respective percentages of the total). A comparison
of the numbers of autologous HSCTs (scenario 1)
and allogeneic HSCTs (scenario 2) shows that the lat-
ter would exceed the former, if donor limitations did
not exist. As expected, the highest HSCT numbers
are found when current indications are expanded
(scenario 4).
Distribution by sex is similar under all 4 scenarios,
with more male than female HSCT recipients. The
distribution by race is also similar under all 4 scenarios.For autologous HSCT, the 2 most common indi-
cations in children are neuroblastoma and central
nervous system (CNS) tumors, whereas in adults
they are MM and lymphoma. For allogeneic HSCT
(scenario 2) and for HSCT in general (scenario 3) leu-
kemia is the most common indication in both age
groups.
When current indications are expanded to include
a larger proportion of individuals with malignancies
considered treatable by HSCT (scenario 4), the most
common cancers treatable with HSCT are leukemia
for children and lymphoma for adults.
Incidences of HSCT, by Age Decade
Table 3 shows the incidences of HSCT by age.
Incidences are considerably higher in the 5th-7th
decades than in the 1st-3rd decades of life, under all
4 scenarios. This ‘‘age effect’’ is observed for men
and women of both racial groups. Table 3 shows that
the higher transplant numbers for men versus women
in Table 1 derive mainly from sex differences in disease
incidences in the 5th–7th age decades.
Cumulative Probabilities of Receiving an HSCT, by
Age Decade
Figure 1 shows that when the incidence rates in
Table 3 are used to calculate cumulative probabilities
by age, there is a sharp increase in probability of
HSCT after age 40.Table 3. Average Annual Incidences* of HSCT per Age Decade, by Sex and Race,† under 4 scenarios‡ §
Age decades
Category 0-10 10-20 20-30 30-40 40-50 50-60 60-70
Scenario 1 Total population 1.0 0.6 1.4 2.0 3.4 7.2 8.6
Caucasian men 1.0 0.7 1.5 2.2 3.7 8.1 11.1
Caucasian women 0.8 0.5 1.2 1.7 3.0 6.0 6.2
African-American men 0.8 0.4 1.0 1.7 3.4 7.6 8.8
African-American Women 0.9 0.4 1.2 2.0 3.2 6.8 6.5
Scenario 2 Total population 2.2 2.1 2.1 3.1 5.5 6.8 4.3
Caucasian men 2.0 1.8 1.9 3.2 6.2 8.8 6.2
Caucasian women 1.6 1.3 1.4 2.4 4.6 4.9 2.8
African-American men 1.7 1.9 1.4 2.5 3.2 5.7 2.0
African-American Women 1.5 1.3 1.3 2.0 2.5 3.7 1.2
Scenario 3 Total population 3.1 2.6 3.3 4.9 8.7 13.6 12.4
Caucasian men 3.0 2.5 3.3 5.2 9.7 16.5 16.9
Caucasian women 2.4 1.7 2.5 3.9 7.3 10.4 8.7
African-American men 2.5 2.3 2.3 4.1 6.4 12.8 10.2
African-American women 2.4 1.7 2.4 3.7 5.6 10.3 7.5
Scenario 4 Total population 6.6 5.8 4.6 6.6 11.2 23.4 47.7
Caucasian men 7.8 5.2 5.2 8.3 14.6 30.5 62.9
Caucasian women 6.7 5.5 4.5 5.7 9.0 19.5 42.2
African-American men 4.7 4.2 4.9 10.2 16.9 30.6 60.4
African-American women 3.9 4.2 5.0 6.1 9.5 21.4 37.6
*Cases/100,000 individuals.
†Incidences could only be calculated for Caucasians and African-Americans (see the Materials and Methods section).
‡For a description of the 4 scenarios, see the Materials and Methods section.
§The numbers under scenario 3 do not always equal the total of scenario 1 plus scenario 2. For an explanation, see the Materials and Methods
section.
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lifetime probabilities of receiving an HSCT are
0.23%, 0.25%, 0.46%, or 0.98%, under scenarios 1,
2, 3 and 4, respectively.
Table 4 shows that when the cumulative probabil-
ities of Figure 1 are stratified by sex and race, the
differences between the incidences for men and
women, as shown in Table 3 for the 5th-7th age
decade, translate into comparable differences between
cumulative probabilities in Table 4 (with the exception
Figure 1. Cumulative probabilities that an HCT has been received
by a specific age, under 4 scenarios. For a description of the 4 scenar-
ios, see the Materials and Methods section. The values under
scenario 3 do not always equal the total of the values under scenario
1 plus scenario 2. For an explanation, see the Materials and Methods
section.of African-American men and women under
scenario 1).
It should be noted that in Table 3 and Table 4, in
a few cases, the HSCT incidences, and the corre-
sponding cumulative probabilities, for the total
population are higher than for each subgroup. This
is because of the higher application of HSCT among
individuals who are not identified as Caucasian or
African-American.
DISCUSSION
Whether autologous or allogeneic stem cells are
used for an HSCT depends on the underlying disease
and the planned treatment strategy. When an immune
anti-cancer effect is wanted, or when an inherited bone
marrow defect in the patient needs correction, or when
a cancer-free autologous graft cannot be harvested
from the patient, an allogeneic transplant becomes
the primary choice. Performing an allogeneic HSCT
depends upon finding a suitable donor, ideally an
HLA-identical relative. Such a donor is, unfortunately,
only available for about a third of patients in the U.S.
[8,9]. The next best option is an HLA-identical or
minimally HLA-mismatched unrelated donor trans-
plant, using cells collected from a healthy adult volun-
teer donor or previously collected and stored UCB
cells made available for public use. In some centers
UCB transplantation is now the preferred choice for
unrelated donor HSCT in children who do not have
an HLA-identical related donor [14]. During the yearsTable 4. Cumulative Probabilities That an HSCT Has Been Received by a Specific Age, by Sex and Race,* under 4 Scenarios† ‡
Age (years)
Category 10 20 30 40 50 60 70
Scenario 1 Total population 0.01% 0.02% 0.03% 0.05% 0.09% 0.15% 0.23%
Caucasian men 0.01% 0.02% 0.03% 0.06% 0.10% 0.17% 0.26%
Caucasian women 0.01% 0.01% 0.03% 0.04% 0.08% 0.13% 0.19%
African-American men 0.01% 0.01% 0.02% 0.04% 0.08% 0.14% 0.19%
African-American women 0.01% 0.01% 0.03% 0.05% 0.08% 0.14% 0.19%
Scenario 2 Total population 0.02% 0.04% 0.07% 0.10% 0.15% 0.21% 0.25%
Caucasian men 0.02% 0.04% 0.06% 0.09% 0.15% 0.23% 0.28%
Caucasian women 0.02% 0.03% 0.05% 0.07% 0.12% 0.16% 0.18%
African-American men 0.02% 0.04% 0.05% 0.08% 0.11% 0.15% 0.16%
African-American women 0.02% 0.03% 0.04% 0.06% 0.09% 0.12% 0.13%
Scenario 3 Total population 0.03% 0.06% 0.09% 0.15% 0.23% 0.36% 0.46%
Caucasian men 0.03% 0.06% 0.09% 0.15% 0.24% 0.39% 0.52%
Caucasian women 0.03% 0.04% 0.07% 0.11% 0.19% 0.28% 0.36%
African-American men 0.03% 0.05% 0.07% 0.11% 0.18% 0.28% 0.34%
African-American women 0.03% 0.04% 0.07% 0.10% 0.16% 0.25% 0.31%
Scenario 4 Total population 0.07% 0.13% 0.18% 0.24% 0.36% 0.60% 0.98%
Caucasian men 0.09% 0.16% 0.21% 0.30% 0.43% 0.61% 1.10%
Caucasian women 0.07% 0.13% 0.17% 0.23% 0.33% 0.53% 0.90%
African-American men 0.05% 0.09% 0.15% 0.25% 0.41% 0.68% 1.07%
African-American women 0.04% 0.09% 0.14% 0.20% 0.30% 0.50% 0.79%
*Cumulative probabilities could only be calculated for Caucasians and African-Americans (see the Materials and Methods section).
†For a description of the 4 scenarios, see the Materials and Methods section.
‡The numbers under Scenario 3 do not always equal the total of scenario 1 plus scenario 2. For an explanation, see the Materials and Methods
section.
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HSCTs performed used adult or cord blood unrelated
donors (CIBMTR data). Despite these alternative
sources of grafts, more than half of patients in need
of transplantation still do not have an available donor.
The average annual number of HSCTs, either
autologous or allogeneic, which we calculated for the
U.S. (about 17,000 under scenario 3, assuming univer-
sal donor availability; Table 1), is similar or higher
than the average annual number of other generally
accepted medical procedures in the U.S., for example,
kidney transplantation, with an average of about
15,000 per year [15] and surgery for cleft palate/cleft
lip, with an average of about 5000 per year [16].
When calculating the lifetime probabilities, several
assumptions were made that deserve discussion. Under
scenario 1, CIBMTR data indicate that the lifetime
probability of undergoing an autologous HSCT in
the U.S. is about 1:400 if the indications for autologous
HSCT do not change much during the next 70 years.
This, of course, may not be true. Advances in HSCT
technology may lead to its use for new indications,
new pharmaceutical developments may replace
HSCT for some diseases, or both may occur; the effect
of these advancements could increase, decrease, or
leave unchanged the lifetime probabilities estimated
in this study. Under scenarios 2 and 3, the lifetime
probabilities are 1:400 and 1:200, respectively, for
undergoing allogeneic HSCT or either autologous
or allogeneic HSCT. Those probabilities are partly
speculative, because of the assumption of universal do-
nor availability. However, these probabilities may be
realized with increased numbers of donors and/or
UCB units and/or strategies to accommodate greater
degrees of donor-recipient HLA disparity. A bank
with sufficient allogeneic UCB units could provide
suitable transplants for most U.S. patients in need, be-
cause of the possibility of using UCBs with 1 or 2 HLA
mismatches [17], and when strategies become available
to overcome limitations of low cell numbers [18-22].
The size required for such a donor bank is discussed
elsewhere [23] and must take into account differences,
if any, in outcome with varying degrees of HLA
matching and varying cell doses [24].
Under scenario 4, the calculated probability of
almost 1:100 is based on the speculation that many
changes in current practice will enable more wide-
spread use of HSCT in the future in patients with
diseases where efficacy has already been demon-
strated. A comparison of the probabilities under
scenarios 3 and 4 shows how much a change in
scenario can affect the lifetime probability of under-
going an HSCT. At the moment, about 17% of
patients who are diagnosed with diseases potentially
treatable with HSCT actually undergo HSCT (as
outlined in the Materials and Methods section), in
contrast to the 50% we empirically selected as an‘‘upper limit.’’ It is unlikely that the percentage would
be higher than this because patients may not require
transplantation, may be treated with other therapies,
may have comorbidities that would preclude trans-
plantation or may have socioeconomic barriers to
transplantation. The usage of HSCT is limited by
consideration of the risk to benefit ratio of this
therapy, which carries significant treatment-related
mortality (TRM), versus other (less aggressive) ther-
apies [4]. Major improvements in safety and efficacy
of HSCT are required to realize scenario 4. It is of
interest that during the study period, we estimated
that 40%-45% of patients diagnosed with MM up
to age 70 years received HSCT (.95% autologous
HSCT). During this time, there was general consen-
sus that autotransplant was the preferred therapy (al-
though more recent studies have brought this into
question) and that the procedure could be safely
done even in older patients.
Regardless of scenario or transplant practice,
yearly HSCT rates would increase if uninsured Amer-
icans, which included 11% of children and 15% of
nonelderly adults in 2003 [25], had full access to health
care. Unequal access to health care may account for
some of the discrepancy between the proportion of
HSCTs received by African-Americans (9%, Table
1, scenario 3) and their representation of about 13%
in the U.S. population [26].
As stated in the Materials and Methods section, our
adjustment for underreporting assumed that trans-
plants reported to the CIBMTR are a simple random
sample of patients receiving transplant. There may
be inherent differences in the types of patients treated
by centers reporting versus not reporting to the
CIBMTR, which would result in a biased adjustment
for underreporting. However, inspection of data
reported to NMDP, BMTInfoNet, and the EBMT,
suggest that CIBMTR is representative. A similar
bias could occur from the use of group-level data
from SEER.
In conclusion, whatever the future developments
in HSCT practice, our results show that the lifetime
probability of undergoing HSCT is much higher
than the probabilities previously reported by others
[27-29], which ranged from 1:2,700 to 1:200,000.
These results are important for planning donor
registries, UCB banks, and health insurance policies.
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